Related Experiment Video
Updated: Feb 2, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast
Jintao Hu1, Julia Y Tsang2, Jianlan Liu3
1Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Abstract:
Human epidermal growth factor receptor 2 (HER2) gene amplification and heterogeneity influence anti-HER2 therapy efficacy, but quantitative assessment of HER2 expression heterogeneity remains scarce. This study evaluates HER2 protein heterogeneity and its effect on neoadjuvant therapy (NAT) outcomes in HER2-positive breast cancer. In total, 295 patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy were included. HER2 expression was quantified by the percentage of HER2-stained cells across intensities, and heterogeneity was assessed using quadratic entropy. The overall pathological complete response (pCR) rate was 51.86%. Patients with HER2 heterogeneity showed a 24.5% pCR rate, significantly <62.5% in patients with HER2 homogeneity (P < .001). HER2 heterogeneity quadratic entropy (HER2-HQE) correlated with the percentage of HER2 immunohistochemistry (IHC) 3+ tumor cells and hormone receptor (HR) status (P < .001). Residual cancer burden (RCB) was significantly associated with HR status, tumor stage, lymph node stage, HER2 IHC 3+ cell percentage, and HQE grade (P ≤ .017). No correlation was found with age, histologic grade, or Ki67 index. In the HER2 IHC 3+ ≥95% subgroup, neither pCR rate nor RCB grade after NAT was associated with traditional clinicopathological parameters, even HER2-HQE and HR status (P ≥ .154). The American Joint Committee on Cancer anatomical stage significantly improved post-NAT for low/intermediate HER2-HQE subgroups (P < .001) but not for high HQE cases. In summary, HER2 heterogeneity and HR status are key predictors of anti-HER2 NAT outcomes. Higher HER2-HQE is associated with increased RCB. Quantifying HER2 heterogeneity via HQE and percentage of HER2 IHC 3+ may help optimize therapeutic strategies in clinical practice.
More Related Videos
10:21Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Gene Therapy
Serial Position Effect